TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from TuHURA Biosciences ( (HURA) ) is now available.
TuHURA Biosciences has reported its third-quarter financial results and provided a corporate update, highlighting its ongoing Phase 3 trial of IFx-2.0 as an adjunctive therapy with Keytruda for advanced Merkel cell carcinoma. The trial, under an SPA agreement with the FDA, aims for accelerated approval. Additionally, TuHURA’s Delta Opioid Receptor technology has been selected for presentations at the ASH 2025 Annual Meeting, indicating its potential impact on overcoming resistance to cancer immunotherapies. The company also announced the appointment of Dr. Michael Turner as Vice President of Immunology and established a $50 million ATM facility to support its operations.
The most recent analyst rating on (HURA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.
TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company focused on developing novel therapeutics to overcome resistance to cancer immunotherapy. The company is engaged in clinical development programs, particularly in the treatment of advanced and metastatic cancers, and is actively working on innovative immune modulating therapies.
Average Trading Volume: 220,487
Technical Sentiment Signal: Sell
Current Market Cap: $114M
Find detailed analytics on HURA stock on TipRanks’ Stock Analysis page.